Arch Therapeutics Nears Final Chapter as Liquidation Plan Proceeds

Arch Therapeutics, which received FDA clearance for its AC5® wound care system, is winding down after failing to generate revenue. Its assets are now being liquidated.

The corporate story of Arch Therapeutics is approaching its conclusion. The medical device firm, which sought creditor protection in April 2025, is now formally entering a winding-down phase. A liquidation strategy approved in December has set the stage for the disposal of the company's remaining assets.

Commercial Failure Despite Regulatory Approval

Market observers saw this outcome coming. The failure to achieve a commercial breakthrough ultimately sealed the company's fate, even after its AC5® wound care system received clearance from the U.S. Food and Drug Administration. The underlying technology, which uses synthetic peptides for hemostasis, never translated the initial market optimism into a sustainable revenue stream.

The financial figures starkly illustrate this disconnect. For the full year 2023, Arch Therapeutics generated only about $75,700 in revenue. This was overshadowed by an operating loss approaching $7 million. The company's shares have traded under the ticker symbol ARTHQ for some time, a designation that marks it as a security of a bankrupt entity.

The Liquidation Process Takes Center Stage

All attention now turns to executing the liquidation plan ratified in December 2025. The primary objectives are the distribution of any remaining cash and the potential sale of intellectual property. The patents covering the AC5® technology represent the last significant asset of value for the bankruptcy estate.

This process typically offers little hope for equity investors to recover their capital. In a liquidation, creditor claims are satisfied first, with shareholders receiving consideration only if funds remain. Given the substantial losses accumulated in prior years, the prospect of a meaningful payout to stockholders appears slim.

The coming months will be characterized by the gradual cessation of all business operations. The administrative dissolution of Arch Therapeutics is expected to be largely complete following the close of its fiscal year on September 30. Whether the sale of its intellectual property yields any unexpected value depends entirely on the level of interest from potential buyers within the wound care sector.